We believe that Cellmid’s FGF5 inhibition assets give them a compelling USP in the global competitive landscape for the US$7bn hair loss and US$24bn anti-aging haircare markets. Hair loss and poor hair quality are increasingly becoming problems caused by poor lifestyle choices and environmental factors (such as stress and nutritional deficiencies), rather than being driven purely by genetics and the aging process. Of great significance is the fact that 40% of women have visible hair loss by the time they are aged 40, which has serious negative consequences to an individual’s psychological and emotional wellbeing. Also, Cellmid’s products, based on 100% natural actives, should benefit from the shift of consumers towards products which have natural ingredients.
In addition, On the 28th May 2019, Cellmid announced the appointment of Bart Wuurman as CEO of the company’s Lyramid subsidiary. The primary purpose of the appointment is to allow Mr. Wuurman to drive a licensing or partnership agreement for Cellmid’s extensive IP over Midkine antibodies. Notable achievements by Mr. Wuurman include his role as CEO at AM-Pharma where he achieved a €600m option deal with Pfizer.
Key risks include, but are not limited to, the possibility that Cellmid are unable to continue growing sales and is unable to reach profitability for its Advangen subsidiary, and the possibility that its Mikdine assets are not able to be successfully commercialised.
The information within this section has been provided by
Mawson Graham
and is for general information purposes only and is not intended to reflect any recommendations or financial advice.
The information in this section has been prepared without taking into account your objectives, financial situation or needs.
For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors,
the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding
any Financial Product mentioned herein.
While it is believed that all information sourced and contained within this section to be accurate at the time of publication,
liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded
by Mawson Graham, its associates, officers, directors, employees and agents.
Past performance is not a reliable indicator of future performance.
Important Disclosure: Mawson Graham, its directors, associates and employees advise that they may hold securities, may have an interest in
and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from
any information mentioned within this section and in documents published within this section.
